featured
-
Does blood hold the key to testing treatments earlier in HD patients?
5 min read
A new study by researchers at Johns Hopkins describes a non-invasive way to track progression of Huntington’s disease. This could be used before patients even start showing symptoms to help test treatments in early stages of disease.
-
A first for CRISPR gene editing could have wider applications for human disease
5 min read
A successful early trial of a drug for Familial Transthyretic Amyloidosis showed that CRISPR gene editing could be safely used in the human body. What does this mean for gene editing in HD?
-
Scientists identify precisely how pridopidine works in models of Huntington’s disease
6 min read
New studies pinpoint precisely how the drug pridopidine works in models of Huntington’s disease
-
Huntington's disease therapeutics conference 2021 – Day 3
6 min read
Catch up on all of the latest updates from day 3 of the 2021 CHDI Huntington’s disease therapeutics conference #HDTC2021
-
Huntington’s disease therapeutics conference 2021 – Day 1
14 min read
Catch up on all of the latest updates from day 1 of the 2021 CHDI Huntington’s disease therapeutics conference #HDTC2021 including presentations from Wave, Roche and Triplet.
-
Huntington's disease therapeutics conference 2021 – Day 2
13 min read
Catch up on all of the latest updates from day 2 of the 2021 CHDI Huntington’s disease therapeutics conference #HDTC2021
-
Huntington’s disease clinical trial round up
12 min read
Catch up on all the latest Huntington's disease clinical trial news in this one stop shop article covering all of the recent developments in making medicines for Huntington's disease
-
Disappointing Results from Wave’s PRECISION-HD1 and 2 Trials
6 min read
Wave Life Sciences shared the disappointing news that their two ASOs in Phase 1/2 trials in HD patients did not successfully lower mutant huntingtin.
-
Details emerge of first Huntington’s disease gene therapy clinical trial
8 min read
UniQure announces key details of its planned trial to assess the safety and ability of AMT-130 gene therapy to lower the problematic huntingtin protein using a ‘single-shot’ virus delivery system.
-
Fresh Updates from First Huntingtin Lowering Study Publication
12 min read
Hot off the presses – New publication gives more details about the results of Ionis and Roche's safety study with a Huntingtin-lowering ASO